Emerging drugs to treat juvenile idiopathic arthritis

Bibliography

• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78
   PubMed Web of Science ®Google Scholar
• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis: new perspectives on classification, pathogenesis and treatment. Lancet 2011; in press
   Google Scholar
• Petty RE, Southwood TR, Baum J, Revision of the proposed classification criteria for juvenile idiopathic arthritides: Durban, 1997. J Rheumatol 1998;25:1991-4
   PubMedGoogle Scholar
• Petty RE, Southwood TR, Manners P, International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2
   PubMed Web of Science ®Google Scholar
• Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol 2003;30:1900-3
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 2005;52:687-93
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 2008;371:998-1006
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (sJIA): 12-week data from the Phase III TENDER Trial. Ann Rheum Dis 2010;69
   Google Scholar
• Pascual V, Allantaz F, Arce E, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
   PubMed Web of Science ®Google Scholar
• Gattorno M, Sormani MP, D'Osualdo A, A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008;58:1823-32
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92
   PubMed Web of Science ®Google Scholar
• Gattorno M, Tassi S, Carta S, Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007;56:3138-48
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55
   PubMed Web of Science ®Google Scholar
• Susic GZ, Stojanovic RM, Pejnovic NN, Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study. Clin Exp Rheumatol 2011; published online, doi:3987 [pii]
   Google Scholar
• Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009;48:972-7
   PubMed Web of Science ®Google Scholar
• Ravelli A, Felici E, Magni-Manzoni S, Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005;52:826-32
   PubMed Web of Science ®Google Scholar
• Ravelli A, Varnier GC, Oliveira S, Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:267-75
   PubMed Web of Science ®Google Scholar
• Magni-Manzoni S, Pistorio A, Labo E, A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:1159-64
   PubMed Web of Science ®Google Scholar
• Ravelli A, Manzoni SM, Viola S, Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. J Rheumatol 2001;28:2100-2
   PubMed Web of Science ®Google Scholar
• Solari N, Viola S, Pistorio A, Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008;59:1571-9
   PubMed Web of Science ®Google Scholar
• Griffin TA, Barnes MG, Ilowite NT, Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum 2009;60:2113-23
   PubMed Web of Science ®Google Scholar
• Barnes MG, Grom AA, Thompson SD, Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum 2010;62:3249-58
   PubMed Web of Science ®Google Scholar
• Bartoli M, Taro M, Magni-Manzoni S, The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:370-4
   PubMed Web of Science ®Google Scholar
• Stoll ML, Lio P, Sundel RP, Nigrovic PA. Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum 2008;59:51-8
   PubMed Web of Science ®Google Scholar
• Stoll ML, Zurakowski D, Nigrovic LE, Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006;54:3564-72
   PubMed Web of Science ®Google Scholar
• Connor JD. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule. Pediatrics 1999;104:610-13
   PubMed Web of Science ®Google Scholar
• Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organization (PRINTO). Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children. BMJ 2000;320:1210-11
   PubMed Web of Science ®Google Scholar
• Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organisation (PRINTO). Networking in pediatrics: the example of the Pediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011; epub ahed of print
   Google Scholar
• Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004;16:566-70
   PubMed Web of Science ®Google Scholar
• Ruperto N, Giannini EH, Pistorio A, Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum 2010;62:3131-9
   PubMed Web of Science ®Google Scholar
• Giannini EH, Lovell DJ, Silverman ED, Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a Phase I/II study. J Rheumatol 1996;23:919-24
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9
   PubMed Web of Science ®Google Scholar
• Damasio MB, Malattia C, Martini A, Toma P. Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatr Radiol 2010;40:985-98
   PubMed Web of Science ®Google Scholar
• Babyn P, Doria AS. Radiologic investigation of rheumatic diseases. Rheum Dis Clin North Am 2007;33:403-40
   PubMed Web of Science ®Google Scholar
• Ravelli A, Ioseliani M, Norambuena X, Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:3087-95
   PubMed Web of Science ®Google Scholar
• Malattia C, Damasio MB, Magnaguagno F, Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1764-72
   PubMed Web of Science ®Google Scholar
• Malattia C, Damasio MB, Pistorio A, Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Ann Rheum Dis 2010; published online, doi:ard.2009.126862 [pii];10.1136/ard.2009.126862 [doi]
   Google Scholar
• Giannini EH, Brewer EJ, Kuzmina N, Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR. double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-9
   PubMed Web of Science ®Google Scholar
• Ruperto N, Murray KJ, Gerloni V, A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201
   PubMed Web of Science ®Google Scholar
• Silverman E, Mouy R, Spiegel L, Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66
   PubMed Web of Science ®Google Scholar
• Van Rossum MA, Fiselier TJ, Franssen MJ, Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808-16
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:465-82
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Horneff G, Schmeling H, Biedermann T, The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, Ten CR, Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ilowite NT, Lovell DJ, Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010;62:3259-64
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Goodman S, Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20
   PubMed Web of Science ®Google Scholar
• Horneff G, De BF, Foeldvari I, Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25
   PubMed Web of Science ®Google Scholar
• Nielsen S, Ruperto N, Gerloni V, Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-92
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 2010; published online, doi:nrrheum.2010.142 [pii];10.1038/nrrheum.2010.142 [doi]
   Google Scholar
• Diak P, Siegel J, La GL, Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24
   PubMed Web of Science ®Google Scholar
• Simard J, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort study. Arthritis Rheum 2010; published online, doi:10.1002/art.27741 [doi]
   Google Scholar
• Ruperto N, Martini A. Pediatric rheumatology: JIA, treatment and possible risk of malignancies. Nat Rev Rheumatol 2011;7:6-7
   PubMed Web of Science ®Google Scholar
• Horneff G, Foeldvari I, Minden K, Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 2011;50:230-6
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Rosenberg AM, Oen KG, Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol 2011;38:760-3
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Li T, Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res 2010;62:1542-51
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; published online, doi:10.1002/art.27431 [doi]
   Google Scholar
• Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res 2009;11:216-27
   Google Scholar
• Simonini G, Cantarini L, Bresci C, Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010;9:674-83
   PubMed Web of Science ®Google Scholar
• Magni-Manzoni S, Ruperto N, Pistorio A, Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ruperto N, Giannini E, Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4
   PubMed Web of Science ®Google Scholar
• Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24:S105-10
   PubMed Web of Science ®Google Scholar
• Lurati A, Salmaso A, Gerloni V, Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009;36:1532-5
   PubMed Web of Science ®Google Scholar
• Foell D, Wulffraat N, Wedderburn LR, Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73
   PubMed Web of Science ®Google Scholar
• Sarkar S, Fox DA. Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am 2010;36:345-66
   PubMed Web of Science ®Google Scholar
• Van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53
   PubMed Web of Science ®Google Scholar
• Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol 2010;40:3312-16
   PubMed Web of Science ®Google Scholar
• Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008;35:515-19
   PubMed Web of Science ®Google Scholar
• Olivito B, Simonini G, Ciullini S, Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis. J Rheumatol 2009;36:2017-24
   PubMed Web of Science ®Google Scholar
• Nistala K, Moncrieffe H, Newton KR, Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008;58:875-87
   PubMed Web of Science ®Google Scholar
• Nistala K, Adams S, Cambrook H, Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci USA 2010;107:14751-6
   PubMed Web of Science ®Google Scholar
• Genovese MC, Van den Bosch F, Roberson SA, LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A Phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39
   PubMed Web of Science ®Google Scholar
• Durez P, Chindalore V, Bittmer B. AIN457, an anti-IL17 antibody, shows goodsafety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial. Ann Rheum Dis 2009;68:125
   Google Scholar
• Milner JD, Brenchley JM, Laurence A, Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-6
   PubMed Web of Science ®Google Scholar
• Puel A, Doffinger R, Natividad A, Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207:291-7
   PubMed Web of Science ®Google Scholar
• Steinman L. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol 2010;11:41-4
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40
   PubMed Web of Science ®Google Scholar
• Krausz S, Boumans MJH, Gerlag DM. A Phase IIa, randomized, placebo-controlled clinical study of Apilimod Mesylate, an oral IL-12/IL-23 inhibitor, in patients with active rheumatoid arthritis. Arthritis Rheum 2010;10(S):S458
   Google Scholar
• Sands BE, Jacobson EW, Sylwestrowicz T, Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2010;16:1209-18
   PubMed Web of Science ®Google Scholar
• Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010;24:553-63
   Google Scholar
• van AS, Agmon-Levin N, Elkayam O, EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Looney RJ, Deodhar A, Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74
   PubMed Web of Science ®Google Scholar
• van Assen S, Holvast A, Benne CA, Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75-81
   PubMed Web of Science ®Google Scholar
• Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008;58:5-14
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B. Rituximab treatment in children: comment on the review by Looney, et al. Arthritis Rheum 2008;58:2583-4
   PubMed Web of Science ®Google Scholar
• Quartier P, Brethon B, Philippet P, Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-13
   PubMed Web of Science ®Google Scholar
• Kasher-Meron M, Uziel Y, Amital H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatology (Oxford) 2009;48:445-6
   PubMed Web of Science ®Google Scholar
• Narvaez J, Diaz-Torne C, Juanola X, Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:607-8
   PubMed Web of Science ®Google Scholar
• Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol 2009;15:363-5
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset still's disease with rituximab. Ann Rheum Dis 2006;65:1117-18
   PubMed Web of Science ®Google Scholar
• Ogilvie EM, Khan A, Hubank M, Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1954-65
   PubMed Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Gaston JH, Ostor AJ. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 2006;45:1448-9
   PubMed Web of Science ®Google Scholar
• Corcione A, Ferlito F, Gattorno M, Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis. Arthritis Res Ther 2009;11:R150
   PubMedGoogle Scholar
• Gregorio A, Gambini C, Gerloni V, Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford) 2007;46:308-13
   PubMed Web of Science ®Google Scholar
• Pesu M, Laurence A, Kishore N, Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-42
   PubMed Web of Science ®Google Scholar
• Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24:513-26
   PubMed Web of Science ®Google Scholar
• Connel CA, Riese R, Wood S. Tasocitinib (CP-690,550), an orally available Janus kinase inhibitor, exhibits sustained safety and efficacy in the treatment of rheumatoid arthritis over 24 months. Arthritis Rheum 2010;10(S):S473
   Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Genovese MC, An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kavanaugh A, Weinblatt ME, An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum 2010; published online, doi:10.1002/art.30114 [doi]
   Google Scholar
• Schett G. Erosive arthritis. Arthritis Res Ther 2007;9(Suppl 1):S2
   PubMedGoogle Scholar
• Masi L, Simonini G, Piscitelli E, Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? J Rheumatol 2004;31:986-91
   PubMed Web of Science ®Google Scholar
• Varsani H, Patel A, van KY, Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). Rheumatology (Oxford) 2003;42:583-90
   PubMed Web of Science ®Google Scholar
• Spelling P, Bonfa E, Caparbo VF, Pereira RM. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scand J Rheumatol 2008;37:439-44
   PubMed Web of Science ®Google Scholar
• Sarma PK, Misra R, Aggarwal A. Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol 2008;27:289-94
   PubMed Web of Science ®Google Scholar
• Dore RK, Cohen SB, Lane NE, Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872-5
   PubMed Web of Science ®Google Scholar
• Deodhar A, Dore RK, Mandel D, Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010;62:569-74
   PubMed Web of Science ®Google Scholar
• Cohen SB, Dore RK, Lane NE, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309
   PubMed Web of Science ®Google Scholar
• Sharp JT, Tsuji W, Ory P, Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:537-44
   PubMed Web of Science ®Google Scholar
• Sobacchi C, Frattini A, Guerrini MM, Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007;39:960-2
   PubMed Web of Science ®Google Scholar